Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 5/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27216594 | 0.88 | DDB1 (0.42) | DDB1CRBNGPR119ACACBCYP11B2 | |
| SCHEMBL26981235 | 0.86 | DDB1 (0.45) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL31306762 | 0.86 | DDB1 (0.45) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL29058508 | 0.85 | DDB1 (0.44) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL2575742 | 0.84 | DDB1 (0.56) | DDB1CRBNGPR119MPOCCNC | |
| SCHEMBL20396064 | 0.84 | DDB1 (0.43) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL25628785 | 0.84 | DDB1 (0.43) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL20396112 | 0.84 | DDB1 (0.43) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL31306767 | 0.83 | ALDH1A1 (0.47) | DDB1CRBNNAMPTGPR119ACACB | |
| SCHEMBL30985005 | 0.82 | USP30 (0.45) | DDB1CRBNNAMPTGPR119ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| EP-2739617-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | Nanjing Allgen Pharma Co. Ltd. (CN) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013013308-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | MET, RET, ALK | DDB1 1115/4885CRBN 661/4885NAMPT 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.